Sir, Comment on 'Transitioning to intravitreal aflibercept following a previous treat-and-extend dosing regimen in neovascular age-related macular degeneration: 24-month results'
We read with interest the article by Homer et al. 1 We would like to make some statistical and clinical observations.
The subset of eyes included received an average of 23.8 ± 18.8 injections of ranibizumab or bevacizumab over a period of 28 ± 20.5 months. In view of such a large standard deviation, it would have been more accurate to mention the median for the above two values. The mean interval between aflibercept injections was noted to be 59.3 days and that between ranibizumab/bevacizumab was noted as 37 ± 6.1 days. Without the mention of standard deviation for aflibercept, it is difficult to gauge a statistical comparison between the two groups as one cannot ascertain whether the distribution of the intervals for the aflibercept group was parametric or nonparametric. Without that information, application of the t-test may not be appropriate.
The inclusion criteria at IRB approval mentions cases with ≥ 6 prior intravitreal ranibizumab/bevacizumab injections. But further in the article, the range of prior injections given mentions 4-62 injections. Whether the pathology can be termed as recalcitrant enough to change the intravitreal agent after just 4 injections is little questionable as past literature shows fairly good longterm response to PRN basis injection of ranibizumab over 1-2 years. 2,3 The treatment protocol for aflibercept followed in this study seems to be 2-monthly injections after the three loading dose injections as authors mention a treatment at a fixed interval of 8 weeks. With that perspective, the fact that the minimum exudation-free period noted was 35 days, it is unclear whether any patient was given repeat aflibercept before 8 weeks.
We would appreciate if the authors could clear the above doubts.
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The author declares no conflict of interest. We thank Dr Dave for his valuable comments and suggestions and appreciate his interest in our manuscript. 1 We agree with the author that it would be appropriate to also provide the median value for the number of prior injections and duration of treatment, in addition to the standard deviation. The study included patients who had received 23.8 ± 18.8 (median 21.5) prior ranibizumab or bevacizumab injections over the previous 28 ± 20.5 (median 24) months. We agree with the author that an assessment of the normality of data is a prerequisite for several statistical tests because normal data is an underlying assumption in parametric testing. The quantitative variables for the treatment interval between the two groups were examined by the Shapiro-Wilk test to determine the distribution, which was found to be normal. Because data was normally distributed, the paired test was used. The mean interval between aflibercept injections was 59.3 ± 7.6 days and that between ranibizumab/ bevacizumab was 37 ± 6.1 days.
We also agree that 4 injections are insufficient to label a patient as recalcitrant. Our study looked at eyes with ≥ 6 prior intravitreal ranibizumab and or bevacizumab injections. We apologize for typographical error incorrectly mentioning the range, which should read 6-62 injections.
The treatment protocol followed in this study was 3-monthly aflibercept injections followed by treatment at a generally fixed interval of 8 weeks, further extended by 2-week intervals at the discretion of the treating physician based on persistent/recurrent intraretinal fluid (IRF)/subretinal fluid (SRF)/sub-retinal pigment epithelium (RPE) fluid, new hemorrhage/SRF/IRF on exam, increase in central subfoveal thickness (CFT) 4100 μm and worsening vision by 41 Snellen line. However, as this was a retrospective study, treatment decisions were not absolutely standardized. The range of interval between aflibercept injections was 35-133 days as mentioned in the abstract. There was a single patient who was administered a repeat intravitreal aflibercept injection at 35 days (ie, before 8 weeks).
We appreciate the author's comments and insight into our study. Given the burden imposed by monthly anti-VEGF treatment and the compounded risk of potential adverse ocular and systemic events, conversion to aflibercept offers an approach to increase treatment 
